Meeting
2016 ASCO Annual Meeting
Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes.
Authors
Neelima Vidula
UC San Francisco, San Francisco, CA
Neelima Vidula , Christina Yau , Denise M Wolf , Hope S. Rugo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 34, 2016 (suppl; abstr 1072)
DOI
10.1200/JCO.2016.34.15_suppl.1072
Abstract #
1072
Poster Bd #
177
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) expression in primary breast cancer (BC); correlations with clinical characteristics and patient outcomes.
First Author: Neelima Vidula
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome.
First Author: Qiang Zhang
Poster
2019 ASCO Annual Meeting
Actionable coalterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
First Author: Arielle Lutterman Heeke
Poster
2014 ASCO Annual Meeting
CK14, FOXA1, and androgen receptor (AR) expression in patients (pts) with triple-negative breast cancer (TNBC).
First Author: Ayca Gucalp